Exploring the clinical utility of a novel multichannel platelet function test in patients with stable coronary disease - Platelet function in stable coronary artery disease

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 50 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•General inclusion criteria:
•Able to provide informed consent
•Age between 18 and 75 years, For the stable ischemic heart disease (SIHD)
•population:
•Evidence of significant stable coronary artery disease defined by one of the
•below mentioned criteria
•*Occurrence of a MI more than one year ago. For MI, only type 1 MI (as
•described in the third universal definition of MI) will be considered
•*Coronary revascularization by either PCI or CABG more than one year ago.
•*Evidence of a significant (more than 50%) coronary stenosis on ICA or CCTA.
•*Evidence of loss of contractile myocardium consistent with MI on echo, CMR or
•*Evidence of myocardial ischemia in two or more myocardial segments on stress
•echocardiography or perfusion imaging by SPECT or CMR, 2. Using oral aspirin as
•a anti platelet drug, For the healthy control population:
•- No additional inclusion criteria. Blood samples will be pre-treated with
•aspirin in vitro.
•- Treatment with a single dose of oral aspirin (100 mg) as a antiplatelet drug
•1 day before blood drawing.

•For the SIHD population:
•* Recent (within one year) myocardial infarction or revascularization by either
•CABG or PCI.
•* Unstable ischemic heart disease (CCS class 4)
•* Planned revascularization within one month, For the healthy control
•population:
•* Subjects currently under any medical care
•* Are currently known with any form of atherosclerotic disease
•* Are currently taking any antiplatelet drug, except for aspirin

发起方

Medisch Universitair Ziekenhuis Maastricht